

---

**FOR GENERAL RELEASE TO THE PUBLIC**  
**November 11, 2020**

**ANNOUNCEMENT REGARDING THE INVESTIGATION BY THE COMPETITION BOARD**

After conducting the preliminary inquiry on some companies including our Company and its subsidiary “Samsun Medikal Grup Özel Sağlık Hizmetleri A.Ş.”, the Competition Board announced on November 10, 2020 that it has decided to initiate an investigation as per its decision dated October 15, 2020 and numbered 20-46/624-M, in order to determine whether there is a violation of The Act on the Protection of Competition No.4054 pursuant to Article 4 of the Law No.4054 and within this context has invited us to put forward our defence.

The fact that the Competition Board has initiated an investigation does not necessarily mean that the companies subject to investigation has actually violated of The Act on the Protection of Competition No.4054 or it is or will be subject to a penalty due to a violation of the Competition Law. Any further developments in the matter will be announced as required by CMB regulations.

We proclaim that our above disclosure is in conformity with the principles set down in “Material Events Communiqué” of Capital Markets Board, and it fully reflects all information coming to our knowledge on the subject matter thereof, and it is in conformity with our books, records and documents, and all reasonable efforts have been shown by our Company in order to obtain all information fully and accurately about the subject matter thereof, and we’re personally liable for the disclosures.

**ENQUIRIES**

---

**Dr. Deniz Can Yücel**

Head of Strategy and Investor Relations

T +90 212 227 5555 (Ext: 1148)

E [deniz.yucel@mlpcare.com](mailto:deniz.yucel@mlpcare.com)